Pasi Janne
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 134,728
H-指数: 163
I10-指数 : 547
出版物: 1,257
Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3
Asli Muvaffak , Qi Pan , Haiyan Yan , Rafael Fernandez
Molecular Cancer Research 12 ( 7) 1055 -1066
51
2014
Effects of Src Inhibitors on Cell Growth and Epidermal Growth Factor Receptor and MET Signaling in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells With Acquired MET Amplification
Takeshi Yoshida , Isamu Okamoto , Wataru Okamoto , Erina Hatashita
Cancer Science 101 ( 1) 167 -172
54
2010
The survival of patients treated for limited stage small cell lung cancer has increased during the past 20 years
P.A Janne , B Freidlin , S Saxman , B.E Johnson
Lung Cancer 29 ( 1) 96
2
2000
The development of a short term in vitro culture system for bronchial biopsy specimens in patients with previously treated or suspected lung carcinoma
P.A Janne , L Margolis , M Means-Markwell , K O'Neil
Lung Cancer 29 ( 1) 176
2000
The Promising Evolution of Targeted Therapeutic Strategies in Cancer.
Tony Mok , Antonio Passaro , Solange Peters , Pasi Antero Jänne
Cancer Discovery 11 ( 4) 810 -814
2021
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer , Pasi Antero Jänne , Tony Mok , Kenneth O’Byrne
Clinical investigation 3 ( 1) 29 -35
2
2013
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer
Lorena Lobo de Figueiredo-Pontes , Daisy Wing-Sze Wong , Vicky Pui-Chi Tin , Lap-Ping Chung
Journal of Thoracic Oncology 9 ( 2) 248 -253
13
2014
Physical mapping and genomic structure of the Lowe syndrome gene OCRL1
R. L. Nussbaum , Pasi A. J�nne , Lawrence Charnas , A. Craig Chinault
Human Genetics 99 ( 2) 145 -150
77
1997
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
Mizuki Nishino , Stephanie Cardarella , Suzanne E. Dahlberg , David M. Jackman
Lung Cancer 79 ( 3) 283 -288
55
2013
Patent 2683559 Summary
PASI A JANNE , JEFFREY ENGELMAN , LEWIS C CANTLEY
Sommaire du brevet 2683559
PASI A JANNE , JEFFREY ENGELMAN , LEWIS C CANTLEY
Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M Positive Lung
Geoffrey R Oxnard , Kenneth Thress , Cloud Paweletz , Daniel Stetson
Journal of Thoracic Oncology 10 ( 9) S207 -S207
48
2015
AZD9291: AN IRREVERSIBLE, POTENT AND SELECTIVE TYROSINE KINASE INHIBITOR (TKI) OF ACTIVATING (EGFRM plus) AND RESISTANCE (T790M) MUTATIONS IN ADVANCED NSCLC
Malcolm Ranson , William Pao , Dong-Wan Kim , Sang-We Kim
JOURNAL OF THORACIC ONCOLOGY 8 S389 -S389
37
2013
AZD9291 in treatment-naïve EGFRm advanced NSCLC: AURA first-line cohort
Suresh S Ramalingam , James Chih-Hsin Yang , Chee Lee , Takayasu Kurata
Journal of Thoracic Oncology 10 ( 9) S319 -S320
14
2015
A phase II trial of eriotinib in previously untreated elderly patients (>= 70 yrs) with advanced NSCLC: Preliminary results
Bruce E Johnson , Joan Lucca , Michael S Rabin , Thomas J Lynch
ANNALS OF ONCOLOGY 15 169 -169
10
2004
Results with dacomitinib (pf-00299804), an irreversible pan-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers
Mark G Kris , David Ross Camidge , Giuseppe Giaccone , Toyoaki Hida
JOURNAL OF THORACIC ONCOLOGY 8 S609 -S610
8
2013
A phase ib study of high-dose intermittent (HDI) afatinib in EGFR t790m mutation-positive non-small cell lung cancer patients with acquired resistance to reversible EGFR TKIS
D Ross Camidge , Pasi A Jaenne , Lecia V Sequist , Vikram Chand
Journal of Thoracic Oncology 8 S893 -S893
4
2013
CLINICAL BENEFIT OF CONTINUING CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Sai-Hong I Ou , Gregory J Riely , Yiyun Tang , Dong-Wan Kim
JOURNAL OF THORACIC ONCOLOGY 8 S294 -S294
4
2013
VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus/-Erlotinib in Non-Small Cell Lung Cancer
Sukhmani K Padda , Primo Lara Jr , Scott N Gettinger , Jeffrey A Engelman
JOURNAL OF THORACIC ONCOLOGY 10 ( 9) S291 -S291
1
2015
Correlative analysis of circulating biomarkers from a phase 1B/2 trial of cabozantinib (C) with or without erlotinib (E) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)
Sukhmani K Padda , Yael Rosenberg-Hasson , Joel W Neal , Scott N Gettinger
JOURNAL OF THORACIC ONCOLOGY 8 S1072 -S1073
1
2013